A novel vehicle for the treatment of psoriasis.
To evaluate the effectiveness of topical use of an aerosol foam combination of calcipotriol 50μg/g plus betamethasone dipropionate 0.5 mg/g (Cal/BD foam, Enstilar®) in adult with moderate plaque psoriasis. 120 male and female adult psoriasis patients (53.3% male) from two Italian dermatological units were enrolled in a 8-weeks prospective study performed between November 2018 to January 2019. Psoriasis Area and Severity Index (PASI) was evaluated at baseline(T0) and 4 weeks (T4) of daily application, and a further evaluation was carried out 4 weeks after suspension (T8). Furthermore the Dermatology Life Quality Index (DLQI) was evaluated at baseline and after 4 weeks of treatment (T4). At baseline, patients presented a mean PASI of 7 ( 7.0 ± 2.1). After 4 weeks (T4) once daily application an important improvement of PASI was observed (1.1 ±0.3). At week 4 DLQI was reduced by 5.5 points from baseline (mean: 12 ±3.1 at T0 vs 6.5 ±1.8 at ). 4 weeks after suspension (T8) mean PASI was 2.6 ±1.9, stable compared to the previous evaluation; only 8.3% of treated patients showed worsening of plaque psoriasis. This study suggested that Cal/BD aerosol foam is a effective topical therapy to treat plaque psoriasis. This article is protected by copyright. All rights reserved.